BioWorld

Nov. 25, 2002

Myriad Genetics Raises $57.3M Through Stock Sale From Shelf

About two weeks after filing a shelf registration statement to sell up to $250 million in securities, Myriad Genetics Inc. is raising $57.3 million through a pursuant offering of 3 million shares of stock. (BioWorld Today) Read More

Altea Series B Raises $17M For Trials Of Lead Products

Vaccine Against Cervical Cancer Racked Up 100 Percent Efficacy In Placebo-Controlled Human Trial

From 'Position Of Strength,' QLT Reduces Staff 18 Percent

Other News To Note

Appointments And Announcements

Correction

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...